AUSTRALIAN NOX66 - RADIOTHERAPY STUDY OPENS
-
late-stage prostate cancer
-
novel attempt to sensitise cancers to low-dose radiation
-
aim to achieve shrinkage of both irradiated and non-irradiated tumours
-
5 radiation oncology clinics in QLD and NSW
Sydney, 27 September 2017: Noxopharm (ASX: NOX) is pleased to announce that the third clinical trial of its lead product, NOX66, is approved to commence recruitment.
The study is to be conducted in men with metastatic castrate-resistant prostate cancer who have no remaining standard therapeutic options. NOX66 is being used in these men as a radio-sensitiser. The objective is to sensitise the cancer cells to radiation to the extent that even a low (palliative) dose of radiotherapy will lead to better tumour responses and increased patient survival. Of particular interest is whether the effect of NOX66 is limited to providing more potent responses in tumours directly exposed to radiation, or whether that anti-cancer effect extends to all other tumours in the body that are not exposed to radiation.
For further information please download PDF attached:
Download this document
